MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Androgenetic Alopecia
Conditions
Androgenetic Alopecia
Trial Timeline
Mar 1, 1998 → —
NCT ID
NCT00396175About MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks is a phase 3 stage product being developed by Organon for Androgenetic Alopecia. The current trial status is completed. This product is registered under clinical trial identifier NCT00396175. Target conditions include Androgenetic Alopecia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00396175 | Phase 3 | Completed |
Competing Products
12 competing products in Androgenetic Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| minoxidil | Johnson & Johnson | Phase 3 | 77 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Cyproterone Acetate (Androcur, BAY94-8367) | Bayer | Pre-clinical | 20 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| VDPHL01 | Veradermics | Phase 2 | 47 |
| VDPHL01 QD + Placebo + VDPHL01 BID + Placebo | Veradermics | Phase 3 | 72 |
| VDPHL01 + Placebo | Veradermics | Phase 2/3 | 60 |
| VDPHL01 + Placebo | Veradermics | Phase 3 | 72 |
| ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection | AbSci | Phase 1/2 | 33 |
| ATI-50002 | Aclaris Therapeutics | Phase 2 | 44 |